Eli Lilly and Company
LLY · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $45,043 | $34,124 | $28,541 | $28,318 |
| % Growth | 32% | 19.6% | 0.8% | – |
| Cost of Goods Sold | $8,418 | $7,082 | $6,630 | $7,313 |
| Gross Profit | $36,624 | $27,042 | $21,912 | $21,006 |
| % Margin | 81.3% | 79.2% | 76.8% | 74.2% |
| R&D Expenses | $10,991 | $9,313 | $7,191 | $6,931 |
| G&A Expenses | $8,132 | $6,941 | $6,068 | $6,142 |
| SG&A Expenses | $8,132 | $6,941 | $6,068 | $6,142 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19,123 | $16,255 | $13,258 | $13,073 |
| Operating Income | $17,502 | $10,787 | $8,653 | $7,933 |
| % Margin | 38.9% | 31.6% | 30.3% | 28% |
| Other Income/Exp. Net | -$4,821 | -$4,233 | -$1,847 | -$1,778 |
| Pre-Tax Income | $12,680 | $6,555 | $6,806 | $6,156 |
| Tax Expense | $2,090 | $1,314 | $562 | $574 |
| Net Income | $10,590 | $5,240 | $6,245 | $5,582 |
| % Margin | 23.5% | 15.4% | 21.9% | 19.7% |
| EPS | 11.76 | 5.83 | 6.57 | 5.85 |
| % Growth | 101.7% | -11.3% | 12.3% | – |
| EPS Diluted | 11.71 | 5.8 | 6.57 | 5.85 |
| Weighted Avg Shares Out | 901 | 899 | 950 | 954 |
| Weighted Avg Shares Out Dil | 904 | 903 | 950 | 954 |
| Supplemental Information | – | – | – | – |
| Interest Income | $175 | $174 | $63 | $25 |
| Interest Expense | $781 | $486 | $332 | $340 |
| Depreciation & Amortization | $1,767 | $1,527 | $1,523 | $1,548 |
| EBITDA | $15,228 | $8,568 | $8,661 | $8,043 |
| % Margin | 33.8% | 25.1% | 30.3% | 28.4% |